ATE384126T1 - Interferon induzierende genetisch veränderte attenuierte viren - Google Patents

Interferon induzierende genetisch veränderte attenuierte viren

Info

Publication number
ATE384126T1
ATE384126T1 AT99927440T AT99927440T ATE384126T1 AT E384126 T1 ATE384126 T1 AT E384126T1 AT 99927440 T AT99927440 T AT 99927440T AT 99927440 T AT99927440 T AT 99927440T AT E384126 T1 ATE384126 T1 AT E384126T1
Authority
AT
Austria
Prior art keywords
interferon
genetically modified
recombinant dna
viral
dna techniques
Prior art date
Application number
AT99927440T
Other languages
English (en)
Inventor
Andrej Y Egorov
Thomas Muster
Adolfo Garcia-Sastre
Peter Palese
Sabine Brandt
Original Assignee
Sinai School Medicine
Egorov Andrej Y Dr
Thomas Muster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine, Egorov Andrej Y Dr, Thomas Muster filed Critical Sinai School Medicine
Application granted granted Critical
Publication of ATE384126T1 publication Critical patent/ATE384126T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99927440T 1998-06-12 1999-06-11 Interferon induzierende genetisch veränderte attenuierte viren ATE384126T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8910398P 1998-06-12 1998-06-12

Publications (1)

Publication Number Publication Date
ATE384126T1 true ATE384126T1 (de) 2008-02-15

Family

ID=22215706

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99927440T ATE384126T1 (de) 1998-06-12 1999-06-11 Interferon induzierende genetisch veränderte attenuierte viren

Country Status (12)

Country Link
US (2) US6468544B1 (de)
EP (1) EP1098961B1 (de)
JP (1) JP4441595B2 (de)
AT (1) ATE384126T1 (de)
AU (1) AU748416B2 (de)
CA (1) CA2334857C (de)
DE (1) DE69937999T2 (de)
DK (1) DK1098961T3 (de)
ES (1) ES2301241T3 (de)
PT (1) PT1098961E (de)
WO (1) WO1999064571A1 (de)
ZA (1) ZA200007403B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69937999T2 (de) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
US6146642A (en) * 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
WO2001064860A2 (en) * 2000-03-02 2001-09-07 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses
WO2001077394A1 (en) * 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US7247619B2 (en) * 2000-05-19 2007-07-24 Univ Leland Stanford Junior Viral vectors useful in induction of humoral or cellular immunity
US20040198146A1 (en) * 2002-12-05 2004-10-07 Murray Robert H. Safe toy balloon closure and sealing device and assemblies using same
US7731974B2 (en) 2003-03-27 2010-06-08 Ottawa Hospital Research Institute Mutant vesicular stomatitis viruses and uses thereof
JP2007524363A (ja) 2003-03-27 2007-08-30 オタワ ヘルス リサーチ インスティチュート 変異体水疱性口内炎ウイルスおよびそれらの使用
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
DK2497492T3 (en) 2004-06-01 2018-11-26 Icahn School Med Mount Sinai Genetically modified swine influenza virus and its applications
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
AT502275B8 (de) * 2005-08-08 2007-08-15 Greenhills Biotechnology Res D Immunantwort-induzierende zusammensetzungen
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
WO2009016433A2 (en) * 2006-09-15 2009-02-05 Ottawa Health Research Institute Oncolytic rhabdovirus
EP1911836A1 (de) 2006-10-12 2008-04-16 AVIR Green Hills Biotechnology Trading GmbH Mediumzusatz für die Virusproduktion
TW200909581A (en) * 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
EP2048237A1 (de) 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replikationsdefizienter Influenza-Virus zur Expression heterologer Sequenzen
EP2045323A1 (de) * 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linearische Expressionskonstrukte zur Herstellung von Partikeln des Influenzavirus
EP2072058A1 (de) 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modifiziertes Influenzavirus
CN102223895B (zh) 2008-11-25 2014-11-05 巴克斯特保健股份有限公司 生产pH稳定的包膜病毒的方法
EP2233568A1 (de) 2009-03-19 2010-09-29 Avir Green Hills Biotechnology Research Development Trade AG Neues Verfahren zur Herstellung eines RNA Virus
CN107365751B (zh) 2008-12-16 2021-07-09 纳米医疗公司 流感疫苗的生产
EP2233152A1 (de) 2009-03-24 2010-09-29 Avir Green Hills Biotechnology Research Development Trade Ag Schnell wachsender reassortanter Influenza-A-Virus
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
ES2557315T3 (es) 2009-07-22 2016-01-25 Baxalta GmbH Nuevo virus de la gripe
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CN103237890A (zh) 2010-06-02 2013-08-07 巴克斯特保健股份有限公司 用于产生rna 病毒的方法和辅助病毒
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
EP4241785B1 (de) 2011-09-20 2026-01-28 Icahn School of Medicine at Mount Sinai Influenzavirus-impfstoffe und verwendungen davon
CN103608453B (zh) 2012-03-02 2018-07-24 思齐乐 流感病毒重配
KR20150110494A (ko) 2012-12-03 2015-10-02 노파르티스 아게 재배열 인플루엔자 a 바이러스
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
SG11201507454XA (en) 2013-03-13 2015-10-29 Novartis Ag Influenza b virus reassortment
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
KR20170122786A (ko) 2015-02-26 2017-11-06 베링거잉겔하임베트메디카게엠베하 2가 돼지 인플루엔자 바이러스 백신
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
MX387420B (es) * 2015-11-24 2025-03-18 Commw Scient Ind Res Org Producción de virus en cultivos celulares.
MX2018015755A (es) 2016-06-15 2019-08-29 Icahn School Med Mount Sinai Proteinas de hemaglutinina de virus de influenza y usos de las mismas.
EP3559216A1 (de) 2016-12-22 2019-10-30 Blue Sky Vaccines GmbH Verfahren zur reinigung eines virus
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
US11339377B2 (en) 2017-11-08 2022-05-24 Bluesky Immunotherapies Gmbh SO3 chromatography for use in a method for virus purification
CA3104297A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020152318A2 (en) 2019-01-24 2020-07-30 Blue Sky Vaccines Gmbh High growth influenza virus
US12545718B2 (en) 2019-04-24 2026-02-10 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
CN115896035B (zh) * 2022-12-22 2024-04-16 苏州沃美生物有限公司 一种应用于病毒扩增的Vero细胞株、其构建方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS5939831A (ja) 1982-08-27 1984-03-05 Biseibutsu Kagaku Kenkyusho:Kk 豚用インフルエンザウイルス不活化ワクチン
US5840520A (en) * 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
DE69311764T2 (de) 1992-05-14 1998-02-05 Polymun Scient Immunbio Forsch Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
WO1998002530A1 (en) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
CA2265554A1 (en) 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
BR9809456B1 (pt) 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
DE69937999T2 (de) * 1998-06-12 2009-01-29 Avir Green Hills Biotechnology Research Development Trade Ag Interferon induzierende genetisch veränderte attenuierte viren

Also Published As

Publication number Publication date
AU4434199A (en) 1999-12-30
CA2334857C (en) 2012-03-20
DE69937999D1 (de) 2008-03-06
EP1098961B1 (de) 2008-01-16
EP1098961A4 (de) 2001-09-12
CA2334857A1 (en) 1999-12-16
JP2002517230A (ja) 2002-06-18
US20030157131A1 (en) 2003-08-21
PT1098961E (pt) 2008-04-23
ZA200007403B (en) 2001-09-03
ES2301241T3 (es) 2008-06-16
EP1098961A1 (de) 2001-05-16
US6866853B2 (en) 2005-03-15
WO1999064571A1 (en) 1999-12-16
US6468544B1 (en) 2002-10-22
JP4441595B2 (ja) 2010-03-31
AU748416B2 (en) 2002-06-06
DE69937999T2 (de) 2009-01-29
DK1098961T3 (da) 2008-05-26

Similar Documents

Publication Publication Date Title
ATE384126T1 (de) Interferon induzierende genetisch veränderte attenuierte viren
WO2023155901A1 (en) Mutant cytidine deaminases with improved editing precision
Yuan et al. Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system
US20230310484A1 (en) Modification of Gene Transcription and Translation Efficiency by 5'UTR Sequence Variation
Gissi et al. The complete mitochondrial DNA sequence of the rabbit, Oryctolagus cuniculus
DE60334310D1 (de) Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
DK0702085T3 (da) Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
DE69737886D1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
JP2009540801A5 (de)
JP2019536462A5 (de)
DE60143564D1 (de) Veränderte rekombinasen zur modifizierung des genoms
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
WO2000003030A3 (en) Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
ATE142700T1 (de) Genetische manipulationen mit von rna-viren abgeleiteten sequenzen enthaltendem rekombinantem dna
EP0910406A4 (de) Rekombinante kaninchen-herpesviren
WO2000061737A3 (en) Production of attenuated negative stranded RNA virus vaccines
DE60227268D1 (de) Knockout-mutante von vaccinia-virus und verwendung davon
MXPA05005202A (es) Vacuna.
TR200002909T2 (tr) Rekombinant potivirüs yapısı ve kullanımı
TR200101445T2 (tr) Kararlı, zayıflatılmış kuduz virüsü mutantları ve bu mutantların canlı aşıları
WO1999057284A3 (en) Attenuated influenza viruses
TR200201081A2 (tr) Zayıflatılmış rekombinant kuduz virüs mutantları ve bu mutantların canlı aşıları
ATE476511T1 (de) Nukleinsäuren von hdv, deren bruchstücken und deren verwendungen
ES2367245T8 (es) Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo.

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 1098961

Country of ref document: EP

EEFA Change of the company name